Lemmy Today

1,493 readers
74 users here now

Welcome to lemmy.today!

About us

🤗 Thanks for joining our little instance here, located in Oregon. The idea is to have a fast, stable instance and allow users to subscribe to whatever content they want from here.

😎 We dont block any other instances. We will keep it that way unless it becomes a moderation problem.

🤠 We will be around for a very long time, so you dont have to worry about us shutting down the instance anytime soon. We like performance and stability in our servers, and will upgrade the instance when its needed.

🥹 Make sure to join a lot of remote communities to get a good feed going. How to do that is explained here.

Lemmy mobile apps

You should start using one of these ASAP since the web browser user interface is quite ugly, even with themes.

Optional Lemmy web browser user interfaces

Rules

Contact the admin

founded 1 year ago
ADMINS
1
2
 
 

Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

3
 
 
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/worldnews by /u/PauloPatricio on 2024-08-23 09:15:00+00:00.

4
 
 

Doctors have begun trialling the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

Now experts are testing a new jab that instructs the body to hunt down and kill cancer cells – then prevents them ever coming back. Known as BNT116 and made by BioNTech, the vaccine is designed to treat non-small cell lung cancer (NSCLC), the most common form of the disease.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

view more: next ›